June 30, 2004 - New drug to prevent lasting brain damage
Pharmos is focused on helping people think more clearly -- with cannabis. The biotechnology company is developing cannabis-related compounds that don't have psychotropic effects as potential treatments for central nervous system disorders. Pharmos' lead drug candidate, dexanabinol, is a neuroprotective compound that could prevent lasting damage from traumatic brain injury. It has received FDA fast track status for this indication. The drug candidate may also limit post-surgery memory loss and cognitive impairment. Other targets for these compounds include stroke, neuropathic pain, multiple sclerosis, and Alzheimer's disease.
The above is not legal advice. That can only come from a qualified attorney who is familiar with all the facts and circumstances of a particular, specific case and the relevant law. See Terms of Use.
